|
With the new ultra-sensitive, high resolution digital infrared cameras
available today a technology that has been developing over the past
20 years is creating renewed interest.
Canadian researchers recently found that infrared imaging of breast
cancers could detect minute temperature variations related to blood
flow and demonstrate abnormal patterns associated with the progression
of tumors. These images or thermograms of the breast were positive for
83% of breast cancers compared to 61% for clinical breast examination
alone and 84% for mammography.
Thermography as a physiologic test, demonstrates heat patterns that
are strongly indicative of breast abnormality, the test can detect subtle
changes in breast temperature that indicate a variety of breast diseases
and abnormalities and once abnormal heat patterns are detected in the
breast, follow-up procedures including mammography are necessary to
rule out or properly diagnose cancer and a host of other breast diseases
such as fibrocystic syndrome, Pagets disease, etc.
By performing thermography years before conventional mammography, a
selected patient population at risk can be monitored more carefully,
and then by accurately utilize mammography or ultrasound as soon as
is possible to detect the actual lesion - (once it has grown large enough
and dense enough to be seen on mammographic film), can increase the
patients treatment options and ultimately improve the outcome.
It is in this role that thermography provides its most practical benefit
to the general public and to the medical profession. It is certainly
an adjunct to the appropriate usage of mammography and not a competitor.
In fact, thermography has the ability to identify patients at the highest
risk and actually increase the effective usage of mammographic imaging
procedures
Until such time as a cure has been found for this
terrible disease, progress must be made in the fields of early detection
and risk evaluation coupled with sound clinical decision making.
Thermography, with its non-radiation, non-contact and
low-cost basis has been clearly demonstrated to be a valuable and safe
early risk marker of breast pathology, and an excellent case management
tool for the ongoing monitoring and treatment of breast disease when
used under carefully controlled clinical protocols.
|



click on an image to view full size
|